title: Feasibility of localized immunosuppression: 3. Preliminary evaluation of organosilicone constructs designed for sustained drug release in a cell transplant environment using dexamethasone.
abstract: As part of our ongoing effort to develop biohybrid devices for pancreatic islet transplantation, we are interested in establishing the feasibility of a localized immune-suppressive approach to avoid or minimize the undesirable side effects of existing systemic treatments. Since biohybrid devices can also incorporate biocompatible scaffold constructs to provide a support environment for the transplanted cells that enhances their engraftment and long-term function, we are particularly interested in an approach that would use the same three-dimensional construct, or part of the same construct, to also provide sustained release of therapeutic agents to modulate the inflammatory and immune responses locally. Within this framework, here, we report preliminary results obtained during the investigation of the suitability of organosilicone constructs for providing sustained localized drug release using small, matrix-type polydimethylsiloxane (PDMS) disks and dexamethasone as a model hydrophobic drug. Following a short burst, long-term steady sustained release was observed under in vitro conditions at levels of 0.1-0.5 microg/day/disk with a profile in excellent agreement with that predicted by the Higuchi equation. To verify that therapeutic levels can be achieved, suppression of LPS-induced activation has been shown in THP-1 cells with disks that have been pre-soaked for up to 28 days. These preliminary results prove the feasibility of this approach where an integral part of the biomaterial construct used to enhance cell engraftment and long-term function also serves to provide sustained local drug release.
authors: Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
authors: Y
authors: Y
authors: Song
authors: E
authors: E
authors: Margolles-Clark
authors: C A
authors: CA
authors: Fraker
authors: J D
authors: JD
authors: Weaver
authors: C
authors: C
authors: Ricordi
authors: A
authors: A
authors: Pileggi
authors: C L
authors: CL
authors: Stabler
authors: P
authors: P
authors: Buchwald
mesh_terms: D000465:Algorithms; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D017690:Cell Transplantation / Q000502:physiology*; D003692:Delayed-Action Preparations; D003907:Dexamethasone / Q000494:pharmacology*; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy; D004129:Dimethylpolysiloxanes; D016503:Drug Delivery Systems; D005079:Excipients; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D008070:Lipopolysaccharides / Q000494:pharmacology; D012828:Silicones / Q000494:pharmacology*; D012995:Solubility; D014181:Transplantation Immunology / Q000187:drug effects*
chemical_list: D000893:Anti-Inflammatory Agents; D003692:Delayed-Action Preparations; D004129:Dimethylpolysiloxanes; D005079:Excipients; D008070:Lipopolysaccharides; D012828:Silicones; C013830:baysilon; D003907:Dexamethasone